dc.contributor.author | Torres-Ruiz Raul, Raúl | |
dc.contributor.author | Benítez-Burraco, Antonio | |
dc.contributor.author | Martínez-Lage, Marta | |
dc.contributor.author | Rodriguez Perales, Sandra | |
dc.contributor.author | García-Bellido, Paloma | |
dc.date.accessioned | 2019-07-02T05:30:43Z | |
dc.date.available | 2019-07-02T05:30:43Z | |
dc.date.issued | 2019-05-02 | |
dc.identifier.citation | BMC Med Genet. 2019;20(1):65. | es_ES |
dc.identifier.issn | 1471-2350 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/7828 | |
dc.description.abstract | BACKGROUND: Mutations in the coding region of FOXP2 are known to cause speech and language impairment. However, it is not clear how dysregulation of the gene contributes to language deficit. Interestingly, microdeletions of the region downstream the gene have been associated with cognitive deficits. METHODS: Here, we investigate changes in FOXP2 expression in the SK-N-MC neuroblastoma human cell line after deletion by CRISPR-Cas9 of two enhancers located downstream of the gene. RESULTS: Deletion of any of these two functional enhancers downregulates FOXP2, but also upregulates the closest 3' gene MDFIC. Because this effect is not statistically significant in a HEK 293 cell line, derived from the human kidney, both enhancers might confer a tissue specific regulation to both genes. We have also found that the deletion of any of these enhancers downregulates six well-known FOXP2 target genes in the SK-N-MC cell line. CONCLUSIONS: We expect these findings contribute to a deeper understanding of how FOXP2 and MDFIC are regulated to pace neuronal development supporting cognition, speech and language. | es_ES |
dc.description.sponsorship | We thank Daniela Moralli, Dianne Newbury and Sonja C. Vernes for comments to a first version of this manuscript.
This project was supported by funds from The University of Oxford (John Fell OUP Research Grant [121/435] awarded to Paloma García-Bellido), the Spanish National Research and Development Plan, Instituto de Salud Carlos III, and FEDER (FIS project no. PI14/01884 to Sandra Rodriguez-Perales), and the Spanish Ministry of Economy and Competitiveness (grant number FFI2016–78034-C2–2-P [AEI/FEDER,UE]) to Antonio Benítez-Burraco). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | BMC | es_ES |
dc.relation.isversionof | Publisher's version | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.subject | CRISPR-genome editing | es_ES |
dc.subject | Chromosomal rearrangement | es_ES |
dc.subject | FOXP2 | es_ES |
dc.subject | Functional enhancers | es_ES |
dc.subject | MDFIC | es_ES |
dc.subject | Spanish | es_ES |
dc.subject | Speech and language impairment | es_ES |
dc.title | Functional characterization of two enhancers located downstream FOXP2 | es_ES |
dc.type | Artículo | es_ES |
dc.rights.license | Atribución-NoComercial-CompartirIgual 4.0 Internacional | * |
dc.identifier.pubmedID | 31046704 | es_ES |
dc.format.volume | 20 | es_ES |
dc.format.number | 1 | es_ES |
dc.format.page | 65 | es_ES |
dc.identifier.doi | 10.1186/s12881-019-0810-2 | es_ES |
dc.contributor.funder | University of Oxford (Reino Unido) | |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1471-2350 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1186/s12881-019-0810-2. | es_ES |
dc.identifier.journal | BMC medical genetics | es_ES |
dc.repisalud.institucion | CNIO | es_ES |
dc.repisalud.orgCNIO | CNIO::Unidades técnicas::Unidad de Citogenética Molecular | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/FFI2016-78034-C2-2-P | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI14/01884 | es_ES |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |